Key result
Patient lipoprotein-deficient serum and isolated IgA paraprotein inhibited LDL binding to cultured human skin fibroblasts by up to 70% versus 0% with control serum.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
We studied a 32-yr-old man with a benign paraproteinemia (IgA) affected by severe nonfamilial hypercholesterolemia. In vitro experiments demonstrated that lipoprotein-deficient serum (LPDS) from the patient inhibited the binding of low density lipoprotein (LDL) to human skin fibroblasts cultured in vitro (up to 70%) whereas LPDS from controls had no effect. Removal of IgA from the patient's serum by immunoprecipitation with mono-specific antisera abolished the inhibition of LDL binding. IgA isolated from the serum of the patient by affinity chromatography inhibited, in a dose-dependent manner, the binding of LDL to human skin fibroblasts in vitro, thus showing an IgA-mediated effect. Ligand-blotting experiments demonstrated that the paraprotein directly interacts with the LDL receptor, thus inhibiting the binding of the lipoprotein. Treatment of the receptor protein with reducing agents blocked the interaction of the antibody with the LDL receptor. From these data we speculate that this autoantibody may be responsible for the severe nonfamilial hypercholesterolemia of the patient.
No takes yet. Share an insight, caveat, or question.
Corsini et al. (1986) conducted a case report in Severe nonfamilial hypercholesterolemia with benign IgA paraproteinemia (n=1). Patient lipoprotein-deficient serum (LPDS) and isolated IgA paraprotein vs. Control lipoprotein-deficient serum (LPDS) was evaluated on Inhibition of low density lipoprotein (LDL) binding to cultured human skin fibroblasts in vitro. Patient lipoprotein-deficient serum and isolated IgA paraprotein inhibited LDL binding to cultured human skin fibroblasts by up to 70% versus 0% with control serum.
Synapse has enriched 10 related papers. Consider them for comparative context: